Physician profile
Daphne B Beech
NPI 1013079490
$4,672.90
in general payments reported to CMS, 2019-2025
15 companies · $76.86 in 2025
The $76.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,639 · 2022: $1,763 · 2023: $1,083 · 2024: $112 · 2025: $76.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,284.70 | 2021-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,123.15 | 2021-2023 | Trulance |
| Abbvie INC. | $497.01 | 2021-2023 | |
| Janssen Biotech, INC. | $341.63 | 2021-2023 | Stelara, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $331.12 | 2021-2022 | |
| Redhill Biopharma INC. | $230.99 | 2021 | |
| Qol Medical, LLC | $184.66 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $134.96 | 2021-2023 | Ocaliva |
| Evoke Pharma, INC. | $124.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $116.55 | 2023 | Austedo |
| Alexion Pharmaceuticals, INC. | $99.99 | 2023 | |
| Novo Nordisk INC | $91.69 | 2023 | |
| Amgen INC. | $79.45 | 2023 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $19.21 | 2021 | |
| Celgene Corporation | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Beech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.